Login Register Cart 0
Review Article

慢性阻塞性肺疾病（COPD）中黄酮类化合物与心血管疾病的减少

卷 26, 期 39, 2019

页: [7048 - 7058] 页: 11

弟呕挨: 10.2174/0929867325666180514100640

价格: $65

摘要

背景：慢性阻塞性肺疾病（COPD）和心血管疾病（CV）通常并存。 COPD和CVD是复杂的疾病，其特征是环境与遗传因素之间存在严格的相互作用。连接这两种疾病的机制是复杂的，多因素的，尚未完全了解，影响了治疗方法。 COPD的特征在于几种合并症，它假设治疗心血管合并症可能会降低发病率和死亡率。类黄酮是植物低分子量次生代谢产物（SMs）的重要类别。来自实验室，流行病学和人类临床研究的令人信服的数据指出了预防CVD风险的重要作用。目的：本综述旨在提供有关类黄酮降低心血管疾病风险的最新信息。结论：目前的研究支持类黄酮预防CVD风险的潜力。建议设计良好的临床研究来评估类黄酮在治疗COPD中CVD合并症的优势和局限性。

关键词: 减少心血管疾病，COPD，类黄酮，病理生理机制，修复组学，炎性疾病，合并症。

« Previous Next »
[1]
Martinez, F.D. Early-life origins of chronic obstructive pulmonary disease. N. Engl. J. Med., 2016, 375(9), 871-878.
[http://dx.doi.org/10.1056/NEJMra1603287] [PMID: 27579637]
[2]
Woodruff, P.G.; Agusti, A.; Roche, N.; Singh, D.; Martinez, F.J. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet, 2015, 385(9979), 1789-1798.
[http://dx.doi.org/10.1016/S0140-6736(15)60693-6] [PMID: 25943943]
[3]
Vanfleteren, L.E.G.W.; Spruit, M.A.; Wouters, E.F.M.; Franssen, F.M.E. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir. Med., 2016, 4(11), 911-924.
[http://dx.doi.org/10.1016/S2213-2600(16)00097-7] [PMID: 27264777]
[4]
Perret, J.L.; Walters, E.H.; Abramson, M.J.; McDonald, C.F.; Dharmage, S.C. The independent and combined effects of lifetime smoke exposures and asthma as they relate to COPD. Expert Rev. Respir. Med., 2014, 8(4), 503-514.
[http://dx.doi.org/10.1586/17476348.2014.905913] [PMID: 24834459]
[5]
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Report 2017.Available at. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ (Accessed Date: 21 August, 2017)
[6]
Brown, J.P.; Martinez, C.H. Chronic obstructive pulmonary disease comorbidities. Curr. Opin. Pulm. Med., 2016, 22(2), 113-118.
[http://dx.doi.org/10.1097/MCP.0000000000000241] [PMID: 26814720]
[7]
Lundbäck, B.; Lindberg, A.; Lindström, M.; Rönmark, E.; Jonsson, A.C.; Jönsson, E.; Larsson, L.G.; Andersson, S.; Sandström, T.; Larsson, K. Obstructive Lung disease in Northern Sweden studies. not 15 but 50% of smokers develop COPD?--report from the obstructive lung disease in Northern Sweden studies. Respir. Med., 2003, 97(2), 115-122.
[http://dx.doi.org/10.1053/rmed.2003.1446] [PMID: 12587960]
[8]
Vestbo, J.; Hurd, S.S.; Agustí, A.G.; Jones, P.W.; Vogelmeier, C.; Anzueto, A.; Barnes, P.J.; Fabbri, L.M.; Martinez, F.J.; Nishimura, M.; Stockley, R.A.; Sin, D.D.; Rodriguez-Roisin, R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med., 2013, 187(4), 347-365.
[http://dx.doi.org/10.1164/rccm.201204-0596PP] [PMID: 22878278]
[9]
Postma, D.S.; Bush, A.; van den Berge, M. Risk factors and early origins of chronic obstructive pulmonary disease. Lancet, 2015, 385(9971), 899-909.
[http://dx.doi.org/10.1016/S0140-6736(14)60446-3] [PMID: 25123778]
[10]
Schamberger, A.C.; Mise, N.; Meiners, S.; Eickelberg, O. Epigenetic mechanisms in COPD: implications for pathogenesis and drug discovery. Expert Opin. Drug Discov., 2014, 9(6), 609-628.
[http://dx.doi.org/10.1517/17460441.2014.913020] [PMID: 24850530]
[11]
Onishi, K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J. Cardiol., 2017, 70(2), 128-134.
[http://dx.doi.org/10.1016/j.jjcc.2017.03.001] [PMID: 28325523]
[12]
Cazzola, M.; Calzetta, L.; Rinaldi, B.; Page, C.; Rosano, G.; Rogliani, P.; Matera, M.G. Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs, 2017, 77(7), 721-732.
[http://dx.doi.org/10.1007/s40265-017-0731-3] [PMID: 28349353]
[13]
Roversi, S.; Fabbri, L.M.; Sin, D-D.; Hawkins, N.M.; Agustí, A. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am. J. Respir. Crit. Care Med., 2016, 194(11), 1319-1336.
[http://dx.doi.org/10.1164/rccm.201604-0690SO] [PMID: 27589227]
[14]
Chen, W.; Thomas, J.; Sadatsafavi, M.; FitzGerald, J.M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir. Med., 2015, 3(8), 631-639.
[http://dx.doi.org/10.1016/S2213-2600(15)00241-6] [PMID: 26208998]
[15]
Yin, H.L.; Yin, S.Q.; Lin, Q.Y.; Xu, Y.; Xu, H.W.; Liu, T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis. Medicine (Baltimore), 2017, 96(19) e6836
[http://dx.doi.org/10.1097/MD.0000000000006836] [PMID: 28489768]
[16]
Kisialiou, A.; Prinzi, G.; Lamonaca, P.; Fini, M.; Bonassi, S.; Russo, P. Pharmacological Management of Chronic Obstructive Pulmonary Disease (COPD). Evidence from a Real-World Perspective. Curr. Med. Chem., 2017.
[17]
Divo, M.; Cote, C.; de Torres, J.P.; Casanova, C.; Marin, J.M.; Pinto-Plata, V.; Zulueta, J.; Cabrera, C.; Zagaceta, J.; Hunninghake, G.; Celli, B. BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2012, 186(2), 155-161.
[http://dx.doi.org/10.1164/rccm.201201-0034OC] [PMID: 22561964]
[18]
Thomson, N.C. Asthma and smoking-induced airway disease without spirometric COPD. Eur. Respir. J., 2017, 49(5) 1602061
[http://dx.doi.org/10.1183/13993003.02061-2016] [PMID: 28461294]
[19]
Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Pre-vention (US) 2010.Available at. https://www.ncbi.nlm.nih.gov/books/NBK53017/ (Accessed Date: 31 August, 2017)
[20]
The health consequences of smoking-50 years of progress: A report of the surgeon general. National center for chronic disease prevention and health promotion (us) of-fice on smoking and health. Atlanta (GA): Centers for disease control and prevention (US) 2014.Available at. https://www.ncbi.nlm.nih.gov/books/NBK179276/?term=How%20Tobacco%20Smoke%20Causes%20Disease%3A%20The%20Biology%20and%20Behavioral%20Basis%20for%20Smoking-Attributable%20Disease (Accessed Date: 31 August, 2017)
[21]
West, R. Tobacco smoking: Health impact, prevalence, correlates and interventions. Psychol. Health, 2017, 32(8), 1018-1036.
[http://dx.doi.org/10.1080/08870446.2017.1325890] [PMID: 28553727]
[22]
Argacha, J.F.; Bourdrel, T.; van de Borne, P. Ecology of the cardiovascular system: A focus on air-related environmental factors. Trends Cardiovasc. Med., 2018, 28(2), 112-126.
[http://dx.doi.org/10.1016/j.tcm.2017.07.013] [PMID: 28826667]
[23]
Fragoso, C.A.; Liu, X.; Fragoso, C.A. Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) in aging populations. COPD, 2016, 13(2), 125-129.
[http://dx.doi.org/10.3109/15412555.2015.1077506] [PMID: 26629987]
[24]
Chronic Obstructive Pulmonary Disease among Adults Aged 18 and Over in the United States, 1998-2009. NCHS Data Brief No 63; National Center for Health Statistics: Hyattsville, MD, 2011.
[25]
Assaggaf, H.; Felty, Q. Gender, estrogen, and obliterative lesions in the lung. Int. J. Endocrinol., 2017, 2017 8475701
[http://dx.doi.org/10.1155/2017/8475701] [PMID: 28469671]
[26]
Barnes, P.J. Mechanisms of development of multimorbidity in the elderly. Eur. Respir. J., 2015, 45(3), 790-806.
[http://dx.doi.org/10.1183/09031936.00229714] [PMID: 25614163]
[27]
Divo, M.J.; Celli, B.R.; Poblador-Plou, B.; Calderón-Larrañaga, A.; de-Torres, J.P.; Gimeno-Feliu, L.A.; Bertó, J.; Zulueta, J.J.; Casanova, C.; Pinto-Plata, V.M.; Cabrera-Lopez, C.; Polverino, F.; Carmona Píréz, J.; Prados-Torres, A.; Marin, J.M. EpiChron—BODE Collaborative Group. Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort. PLoS One, 2018, 13(2) e0193143
[http://dx.doi.org/10.1371/journal.pone.0193143] [PMID: 29470502]
[28]
Panche, A.N.; Diwan, A.D.; Chandra, S.R. Flavonoids: an overview. J. Nutr. Sci., 2016, 5 e47
[http://dx.doi.org/10.1017/jns.2016.41] [PMID: 28620474]
[29]
Kumar, S.; Pandey, A.K. Chemistry and biological activities of flavonoids: an overview. ScientificWorldJournal, 2013, 2013 162750
[http://dx.doi.org/10.1155/2013/162750] [PMID: 24470791]
[30]
Russo, P.; Del Bufalo, A.; Cesario, A. Flavonoids acting on DNA topoisomerases: recent advances and future perspectives in cancer therapy. Curr. Med. Chem., 2012, 19(31), 5287-5293.
[http://dx.doi.org/10.2174/092986712803833272] [PMID: 22998568]
[31]
Menezes, R.; Rodriguez-Mateos, A.; Kaltsatou, A.; González-Sarrías, A.; Greyling, A.; Giannaki, C.; Andres-Lacueva, C.; Milenkovic, D.; Gibney, E.R.; Dumont, J.; Schär, M.; Garcia-Aloy, M.; Palma-Duran, S.A.; Ruskovska, T.; Maksimova, V.; Combet, E.; Pinto, P. Impact of flavonols on cardiometabolic biomarkers: A meta-analysis of randomized controlled human trials to explore the role of inter-individual variability. Nutrients, 2017, 9(2) E117
[http://dx.doi.org/10.3390/nu9020117] [PMID: 28208791]
[32]
Lin, X.; Zhang, I.; Li, A.; Manson, J.E.; Sesso, H.D.; Wang, L.; Liu, S. Cocoa flavanol intake and biomarkers for cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials. J. Nutr., 2016, 146(11), 2325-2333.
[http://dx.doi.org/10.3945/jn.116.237644] [PMID: 27683874]
[33]
Hooper, L.; Kroon, P.A.; Rimm, E.B.; Cohn, J.S.; Harvey, I.; Le Cornu, K.A.; Ryder, J.J.; Hall, W.L.; Cassidy, A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr., 2008, 88(1), 38-50.
[http://dx.doi.org/10.1093/ajcn/88.1.38] [PMID: 18614722]
[34]
Tokede, O.A.; Gaziano, J.M.; Djoussé, L. Effects of cocoa products/dark chocolate on serum lipids: a meta-analysis. Eur. J. Clin. Nutr., 2011, 65(8), 879-886.
[http://dx.doi.org/10.1038/ejcn.2011.64] [PMID: 21559039]
[35]
Ried, K.; Fakler, P.; Stocks, N.P. Effect of cocoa on blood pressure. Cochrane Database Syst. Rev., 2017, 4 CD008893
[http://dx.doi.org/10.1002/14651858.CD008893.pub3] [PMID: 28439881]
[36]
Desch, S.; Schmidt, J.; Kobler, D.; Sonnabend, M.; Eitel, I.; Sareban, M.; Rahimi, K.; Schuler, G.; Thiele, H. Effect of cocoa products on blood pressure: systematic review and meta-analysis. Am. J. Hypertens., 2010, 23(1), 97-103.
[http://dx.doi.org/10.1038/ajh.2009.213] [PMID: 19910929]
[37]
Ried, K.; Sullivan, T.; Fakler, P.; Frank, O.R.; Stocks, N.P. Does chocolate reduce blood pressure? A meta-analysis. BMC Med., 2010, 8, 39.
[http://dx.doi.org/10.1186/1741-7015-8-39] [PMID: 20584271]
[38]
Zhu, Y.; Bo, Y.; Wang, X.; Lu, W.; Wang, X.; Han, Z.; Qiu, C. The effect of anthocyanins on blood pressure: A PRISMA-compliant meta-analysis of randomized clinical trials. Medicine (Baltimore), 2016, 95(15) e3380
[http://dx.doi.org/10.1097/MD.0000000000003380] [PMID: 27082604]
[39]
Sahebkar, A. Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr., 2017, 57(4), 666-676.
[http://dx.doi.org/10.1080/10408398.2014.948609] [PMID: 25897620]
[40]
Sahebkar, A.; Simental-Mendía, L.E.; Giorgini, P.; Ferri, C.; Grassi, D. Lipid profile changes after pomegranate consumption: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine, 2016, 23(11), 1103-1112.
[http://dx.doi.org/10.1016/j.phymed.2015.12.014] [PMID: 26857863]
[41]
Sahebkar, A. A systematic review and meta-analysis of the effects of pycnogenol on plasma lipids. J. Cardiovasc. Pharmacol. Ther., 2014, 19(3), 244-255.
[http://dx.doi.org/10.1177/1074248413511691] [PMID: 24346156]
[42]
Qi, n Y.; Niu, K.; Zeng, Y.; Liu, P.; Yi, L.; Zhang, T.; Zhang, Q.Y.; Zhu, -JD.; Mi, YM-T. Isoflavones for hypercholesterolaemia in adults. Cochrane Database Syst. Rev., 2013, 6 CD009518
[http://dx.doi.org/10.1002/14651858.CD009518.pub2] [PMID: 23744562]
[43]
Jia, L.; Liu, X.; Bai, Y.Y.; Li, S.H.; Sun, K.; He, C.; Hui, R. Short-term effect of cocoa product consumption on lipid profile: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr., 2010, 92(1), 218-225.
[http://dx.doi.org/10.3945/ajcn.2009.28202] [PMID: 20504978]
[44]
Jiang, W.; Wei, H.; He, B. Dietary flavonoids intake and the risk of coronary heart disease: a dose-response meta-analysis of 15 prospective studies. Thromb. Res., 2015, 135(3), 459-463.
[http://dx.doi.org/10.1016/j.thromres.2014.12.016] [PMID: 25555317]
[45]
Wang, Z.M.; Nie, Z.L.; Zhou, B.; Lian, X.Q.; Zhao, H.; Gao, W.; Wang, Y.S.; Jia, E.Z.; Wang, L.S.; Yang, Z.J. Flavonols intake and the risk of coronary heart disease: a meta-analysis of cohort studies. Atherosclerosis, 2012, 222(1), 270-273.
[http://dx.doi.org/10.1016/j.atherosclerosis.2012.02.026] [PMID: 22429503]
[46]
Li, S.H.; Tian, H.B.; Zhao, H.J.; Chen, L.H.; Cui, L.Q. The acute effects of grape polyphenols supplementation on endothelial function in adults: meta-analyses of controlled trials. PLoS One, 2013, 8(7) e69818
[http://dx.doi.org/10.1371/journal.pone.0069818] [PMID: 23894543]
[47]
Li, S.H.; Liu, X.X.; Bai, Y.Y.; Wang, X.J.; Sun, K.; Chen, J.Z.; Hui, R.T. Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials. Am. J. Clin. Nutr., 2010, 91(2), 480-486.
[http://dx.doi.org/10.3945/ajcn.2009.28203] [PMID: 19923372]
[48]
Beavers, D.P.; Beavers, K.M.; Miller, M.; Stamey, J.; Messina, M.J. Exposure to isoflavone-containing soy products and endothelial function: a Bayesian meta-analysis of randomized controlled trials. Nutr. Metab. Cardiovasc. Dis., 2012, 22(3), 182-191.
[http://dx.doi.org/10.1016/j.numecd.2010.05.007] [PMID: 20709515]
[49]
McCullough, M.L.; Chevaux, K.; Jackson, L.; Preston, M.; Martinez, G.; Schmitz, H.H.; Coletti, C.; Campos, H.; Hollenberg, N.K. Hypertension, the Kuna, and the epidemiology of flavanols. J. Cardiovasc. Pharmacol., 2006, 47(Suppl. 2), S103-S109.
[http://dx.doi.org/10.1097/00005344-200606001-00003] [PMID: 16794446]
[50]
Lawes, C.M.; Vander Hoorn, S.; Rodgers, A. International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet, 2008, 371(9623), 1513-1518.
[http://dx.doi.org/10.1016/S0140-6736(08)60655-8] [PMID: 18456100]
[51]
Martiniuk, A.L.; Lee, C.M.; Lawes, C.M.; Ueshima, H.; Suh, I.; Lam, T.H.; Gu, D.; Feigin, V.; Jamrozik, K.; Ohkubo, T.; Woodward, M. Asia-pacific cohort studies collaboration. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J. Hypertens., 2007, 25(1), 73-79.
[http://dx.doi.org/10.1097/HJH.0b013e328010775f] [PMID: 17143176]
[52]
Kim, S.H.; Park, J.H.; Lee, J.K.; Heo, E.Y.; Kim, D.K.; Chung, H.S. Chronic obstructive pulmonary disease is independently associated with hypertension in men: A survey design analysis using nationwide survey data. Medicine (Baltimore), 2017, 96(19) e6826
[http://dx.doi.org/10.1097/MD.0000000000006826] [PMID: 28489760]
[53]
Kaufman, T.; Justeson, J. History of the Word for ‘Cacao’ and Related Terms in Ancient Meso-America. In: McNeil, C. L. Chocolate in Mesoamerica: A Cultural History of Cacao; University Press of Florida, 2006; p. 121.
[54]
Magrone, T.; Russo, M.A.; Jirillo, E.E. Cocoa and dark chocolate polyphenols: From biology to clinical applications. Front. Immunol., 2017, 8, 677.
[http://dx.doi.org/10.3389/fimmu.2017.00677] [PMID: 28649251]
[55]
Fraga, C.G.; Litterio, M.C.; Prince, P.D.; Calabró, V.; Piotrkowski, B.; Galleano, M. Cocoa flavanols: effects on vascular nitric oxide and blood pressure. J. Clin. Biochem. Nutr., 2011, 48(1), 63-67.
[http://dx.doi.org/10.3164/jcbn.11-010FR] [PMID: 21297914]
[56]
Schnorr, O.; Brossette, T.; Momma, T.Y.; Kleinbongard, P.; Keen, C.L.; Schroeter, H.; Sies, H. Cocoa flavanols lower vascular arginase activity in human endothelial cells in vitro and in erythrocytes in vivo. Arch. Biochem. Biophys., 2008, 476(2), 211-215.
[http://dx.doi.org/10.1016/j.abb.2008.02.040] [PMID: 18348861]
[57]
Grassi, D.; Desideri, G.; Mai, F.; Martella, L.; De Feo, M.; Soddu, D.; Fellini, E.; Veneri, M.; Stamerra, C.A.; Ferri, C. Cocoa, glucose tolerance, and insulin signaling: cardiometabolic protection. J. Agric. Food Chem., 2015, 63(45), 9919-9926.
[http://dx.doi.org/10.1021/acs.jafc.5b00913] [PMID: 26126077]
[58]
Persson, I.A.; Persson, K.; Hägg, S.; Andersson, R.G. Effects of cocoa extract and dark chocolate on angiotensin-converting enzyme and nitric oxide in human endothelial cells and healthy volunteers--a nutrigenomics perspective. J. Cardiovasc. Pharmacol., 2011, 57(1), 44-50.
[http://dx.doi.org/10.1097/FJC.0b013e3181fe62e3] [PMID: 20966764]
[59]
Moreno-Ulloa, A.; Cid, A.; Rubio-Gayosso, I.; Ceballos, G.; Villarreal, F.; Ramirez-Sanchez, I. Effects of (-)-epicatechin and derivatives on nitric oxide mediated induction of mitochondrial proteins. Bioorg. Med. Chem. Lett., 2013, 23(15), 4441-4446.
[http://dx.doi.org/10.1016/j.bmcl.2013.05.079] [PMID: 23791569]
[60]
Martin, M.A.; Goya, L.; Ramos, S. Antidiabetic actions of cocoa flavanols. Mol. Nutr. Food Res., 2016, 60(8), 1756-1769.
[http://dx.doi.org/10.1002/mnfr.201500961] [PMID: 26824673]
[61]
Lococo, F.; Cesario, A.; Del Bufalo, A.; Ciarrocchi, A.; Prinzi, G.; Mina, M.; Bonassi, S.; Russo, P. Novel therapeutic strategy in the management of COPD: a systems medicine approach. Curr. Med. Chem., 2015, 22(32), 3655-3675.
[http://dx.doi.org/10.2174/0929867322666150904113032] [PMID: 26337103]
[62]
Barnes, P.J. Cellular and molecular mechanisms of asthma and COPD. Clin. Sci. (Lond.), 2017, 131(13), 1541-1558.
[http://dx.doi.org/10.1042/CS20160487] [PMID: 28659395]
[63]
Kim, H.P.; Lim, H.; Kwon, Y.S. Therapeutic potential of medicinal plants and their constituents on lung inflammatory disorders. Biomol. Ther. (Seoul), 2017, 25(2), 91-104.
[http://dx.doi.org/10.4062/biomolther.2016.187] [PMID: 27956716]
[64]
Santana, F.P.; Pinheiro, N.M.; Mernak, M.I.; Righetti, R.F.; Martins, M.A.; Lago, J.H.; Lopes, F.D.; Tibério, I.F.; Prado, C.M. Evidences of herbal medicine-derived natural products effects in inflammatory lung diseases. Mediators Inflamm., 2016, 2016 2348968
[http://dx.doi.org/10.1155/2016/2348968] [PMID: 27445433]
[65]
Weseler, A.R.; Geraets, L.; Moonen, H.J.; Manders, R.J.; van Loon, L.J.; Pennings, H.J.; Wouters, E.F.; Bast, A.; Hageman, G.J. Poly (ADP-ribose) polymerase-1-inhibiting flavonoids attenuate cytokine release in blood from male patients with chronic obstructive pulmonary disease or type 2 diabetes. J. Nutr., 2009, 139(5), 952-957.
[http://dx.doi.org/10.3945/jn.108.102756] [PMID: 19321592]
[66]
Liu, X.J.; Bao, H.R.; Zeng, X.L.; Wei, J.M. Effects of resveratrol and genistein on nuclear factorκB, tumor necrosis factorα and matrix metalloproteinase9 in patients with chronic obstructive pulmonary disease. Mol. Med. Rep., 2016, 13(5), 4266-4272.
[http://dx.doi.org/10.3892/mmr.2016.5057] [PMID: 27035424]
[67]
Hirayama, F.; Lee, A.H.; Binns, C.W.; Hiramatsu, N.; Mori, M.; Nishimura, K. Dietary intake of isoflavones and polyunsaturated fatty acids associated with lung function, breathlessness and the prevalence of chronic obstructive pulmonary disease: possible protective effect of traditional Japanese diet. Mol. Nutr. Food Res., 2010, 54(7), 909-917.
[http://dx.doi.org/10.1002/mnfr.200900316] [PMID: 20112297]
[68]
Adesanoye, D.T.; Willey, C.J. Does cardiovascular comorbidity influence the prescribing of bronchodilators in chronic obstructive pulmonary disease? Ann. Pharmacother., 2017, 51(10), 855-861.
[http://dx.doi.org/10.1177/1060028017712531] [PMID: 28573879]
[69]
Loscalzo, J.; Kohane, I.; Barabasi, A.L. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol. Syst. Biol., 2007, 3, 124.
[http://dx.doi.org/10.1038/msb4100163] [PMID: 17625512]
[70]
Wagner, A.K. TBI rehabilomics research: an exemplar of a biomarker-based approach to precision care for populations with disability. Curr. Neurol. Neurosci. Rep., 2017, 17(11), 84-89.
[http://dx.doi.org/10.1007/s11910-017-0791-5] [PMID: 28929311]

Rights & Permissions Print Cite
Article Metrics
24
© 2024 Bentham Science Publishers | Privacy Policy